Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Pacific Biosciences of California Inc before investing.

In this article, we go over a few key elements for understanding Pacific Biosciences of California Inc’s stock price such as:

• Pacific Biosciences of California Inc’s current stock price and volume
• Why Pacific Biosciences of California Inc’s stock price changed recently
• Upgrades and downgrades for PACB from analysts
• PACB’s stock price momentum as measured by its relative strength

About Pacific Biosciences of California Inc (PACB)

Before we jump into Pacific Biosciences of California Inc’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

Pacific Biosciences of California, Inc. is a life science technology company. The Company designs, develops and manufactures advanced sequencing solutions to help scientists and clinical researchers resolve genetically complex problems. The Company has developed Single Molecule, Real-Time (SMRT) technology, which accurately detects the nucleotide sequence and epigenetic status of individual deoxyribonucleic acid (DNA) molecules. The Company?s products include Revio, Sequel, Sequel II and Sequel IIe instruments that conduct, monitor, and analyze single-molecule biochemical reactions in real time. The instruments use extremely sensitive imaging systems to collect the light pulses emitted by fluorescent reagents allowing the observation of biological processes. Once sequencing is started, the real-time data is delivered to the system?s primary analysis pipeline, which outputs base identity and quality values.

Want to learn more about Pacific Biosciences of California Inc’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Pacific Biosciences of California Inc.

Pacific Biosciences of California Inc’s Stock Price as of Market Close

As of September 25, 2023, 4:00 PM, CST, Pacific Biosciences of California Inc’s stock price was $8.46.

Pacific Biosciences of California Inc is down 5.37% from its previous closing price of $8.94.

During the last market session, Pacific Biosciences of California Inc’s stock traded between $8.88 and $9.11. Currently, there are 250.07 million shares of Pacific Biosciences of California Inc stock available for purchase.

Unfortunately, Pacific Biosciences of California Inc’s P/E ratio is not significant enough to use for stock price evaluation. We recommend investors evaluate other financial metrics to understand its overall valuation.

Pacific Biosciences of California Inc Stock Price History

Pacific Biosciences of California Inc’s (PACB) price is currently down 25% so far this month.

During the month of September, Pacific Biosciences of California Inc’s stock price has reached a high of $11.96 and a low of $8.42.

Over the last year, Pacific Biosciences of California Inc has hit prices as high as $14.55 and as low as $4.97. Year to date, Pacific Biosciences of California Inc’s stock is down 58.65%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Pacific Biosciences of California Inc Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of September 22, 2023, there were 0 analysts who downgraded Pacific Biosciences of California Inc’s stock and 1 analyst who upgraded over the last month.

Additionally, you'll want to evaluate Pacific Biosciences of California Inc’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Pacific Biosciences of California Inc’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Pacific Biosciences of California Inc’s current valuation based on AAII’s Value Grade is a F, which means it is considered to be Ultra Expensive.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Pacific Biosciences of California Inc (PACB) by visiting AAII Stock Evaluator.

Relative Price Strength of Pacific Biosciences of California Inc

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of September 22, 2023, Pacific Biosciences of California Inc has a weighted four-quarter relative price strength of 5.84%, which translates to a Momentum Score of 82 and is considered to be Very Strong.

Want to learn more about how Pacific Biosciences of California Inc is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Pacific Biosciences of California Inc Stock Price: Bottom Line

As of September 25, 2023, Pacific Biosciences of California Inc’s stock price is $8.46, which is down 5.37% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Pacific Biosciences of California Inc stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.